

ASTRAZENECA PLC
Form 6-K
June 18, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of June 2014

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES:

Edgar Filing: ASTRAZENECA PLC - Form 6-K

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:ii AstraZeneca PLC

2 Reason for the notification

(please tick the appropriate box or boxes):

An acquisition or disposal of voting rights Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached No

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments No

An event changing the breakdown of voting rights No

Other (please specify):

3. Full name of person(s) subject to the notification obligation:iii Invesco Limited

4. Full name of shareholder(s)

(if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or reached:v 17 April 2014

6. Date on which issuer notified: 17 June 2014

7. Threshold(s) that is/are crossed or reached:vi, vii 5%

8. Notified details:

A: Voting rights attached to sharesviii, ix

Class/type of shares	Situation previous to the triggering transaction		Resulting situation after the triggering transaction			
	Number of Shares	Number of Voting Rights	Number of shares Direct	Number of voting rights Directxi	Number of voting rights Indirectxii	% of voting rights x Indirect
Ordinary Shares GB0009895292	72,920,319	72,920,319			63,033,761	4.99%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration datexiii	Exercise/ Conversion Periodxiv	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xvi

Resulting situation after the triggering transaction

Type of financial instrument	Exercise price	Expiration datexvii	Exercise/ Conversion Periodxviii	Number of voting rights instrument refers to	% of voting rightsxix, xx

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Conversion
periodxviii

Nominal

Delta

Total (A+B+C)

Number of voting rights

63,033,761

Percentage of voting rights

4.99%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:xxi

Invesco Advisers Inc. - 182,047

Invesco Asset Management Japan - 75,034

Invesco Asset Management Limited - 16,790,150

Invesco Asset Management S.A (France) - 76,196

Invesco PowerShares Capital Management LLC - 158,278

Invesco GT Management Ltd - 39,146

Invesco Hong Kong Limited - 1,155

Invesco Fund Managers Limited - 45,006,926

Invesco Asset Management Limited GmbH - 667,087

Van Kampen Asset Management - 37,742

Proxy Voting:

10. Name of the proxy holder:

Invesco Limited

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Sam Edwards

15. Contact telephone number:

01491 416381

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Date: 18 June 2014

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary